Last updated: June 11, 2026
Executive summary: Mannitol 10% (commonly described as mannitol injection, 10% w/v) is supplied through global sterile injectables manufacturers and regional contract packagers. The supplier set depends on country-specific marketing authorizations and distributor networks. For procurement and IP-risk screening, focus on (1) the specific strength and dosage form (“mannitol injection 10%” or “mannitol 10% w/v, IV”), (2) whether it is packaged as vials or flexible bags, and (3) GMP sterile manufacturing footprint and regulatory approvals.
What companies supply Mannitol 10% injection for IV use?
The “mannitol 10%” market is typically sourced from manufacturers of sterile solutions, including generics and branded distributors, with product access varying by jurisdiction and tender contracts.
Core supply channels
- Marketing authorization holders (MAHs): The legal entity that holds the approval for “mannitol injection 10%” in a country.
- Local wholesalers/distributors: Often the first procurement interface for hospitals.
- Contract manufacturers (CMOs): Sterile solution filling and packaging for MAHs; sourcing may be visible only via label/packaging.
- GPO and tender aggregators: Contract structures that consolidate demand and determine the “approved supplier list” per region.
Procurement-critical product identifiers
- Strength: 10% w/v (commonly stated as 10 g/100 mL)
- Dosage form: IV infusion/injection solution
- Primary container: vials and/or infusion bags
- Presentation size: often 100 mL and 250 mL (varies by country and supplier)
Which manufacturers make Mannitol injection 10% (vials vs infusion bags)?
Supplier landscape typically splits by container type because aseptic filling lines and packaging formats differ.
Vial presentations
- Usually single-dose vial formats for pharmacies and acute care settings.
- Tends to map to manufacturers with high aseptic vial capacity.
Infusion bag presentations
- Often preferred for large-volume IV workflows.
- Requires compatible bag materials and validated leachables/extractables testing.
How do IV Mannitol 10% suppliers differ by regulatory market (US, EU, UK, Canada)?
Mannitol 10% is regulated as a sterile parenteral product with country-specific marketing authorizations. Supplier eligibility changes with local approvals.
United States (FDA)
- US availability is governed by ANDA/generic listings and Orange Book status, plus label approval for sterile injectables.
- US procurement depends on which label (NDC) is stocked by distributors and formularies.
European Union and UK
- Supplier access is driven by national or centralized approvals and local batch release.
- Tender rules often constrain procurement to MAHs with established local distribution and QP release readiness.
Canada
- Market access hinges on Health Canada approvals and importer/distributor networks.
What is the Orange Book status of Mannitol 10% in the US?
Featured procurement question for planners: whether the product is branded, generic, or tied to any exclusivity or patent-protected formulation.
- Mannitol 10% products in the US often appear as generic sterile parenterals rather than proprietary therapeutics.
- Patent/exclusivity analysis should be done at the NDC level because formulations, container types, and packaging may carry different regulatory statuses.
What patents affect Mannitol 10% suppliers and generic entry risks?
For procurement, the legal risk usually concentrates in:
- Process and manufacturing method patents (sterile solution preparation, purification, aseptic filling)
- Container and packaging patents (bag/vial materials, closure systems)
- Method-of-use or dosing patents are less common for classic excipients like mannitol, but formulation or stability improvements can exist.
How supplier switching can trigger IP or quality constraints
- If a buyer qualifies a specific NDC/container, switching may require:
- new supplier qualification
- stability data review under local storage conditions
- compatibility assessment for IV co-administration protocols
- verification of sterility assurance and endotoxin limits
When can hospitals switch Mannitol 10% suppliers without supply disruption?
Operational timing differs from drug exclusivity timelines because sterile injectables are frequently constrained by:
- aseptic line capacity
- raw material supply continuity (mannitol feedstock)
- batch release throughput at local importers
- seasonal demand surges in some regions
Supply risk indicators used by procurement teams
- Manufacturer lead times and historical fill rates
- Availability by container type (bags often have different lead times than vials)
- Distributor allocation practices during shortages
Which distributor networks sell Mannitol injection 10% to hospitals and wholesalers?
In practice, the supplier most buyers interact with is the distributor, not the MAH.
Common distributor structures
- Hospital group purchasing organizations (GPOs)
- National wholesalers with cold-chain and sterile dispensing capabilities
- Regionally approved procurement lists
Qualification checklist for distribution
- Verify NDC match to approved formulary listing
- Confirm packaging integrity on receipt (seal, overwrap, bag closure)
- Batch-level documentation availability (COA, sterility, endotoxin, lot release papers)
- Traceability for recalls
How to source Mannitol 10%: GMP, aseptic processing, and release testing
Procurement and quality teams typically screen sterile injectable suppliers using:
Aseptic manufacturing requirements
- Sterile filtration and validated aseptic process controls
- Environmental monitoring (viable/non-viable counts)
- Media fill performance
- Container closure integrity testing
Release specifications commonly reviewed
- Assay and concentration compliance (10% w/v tolerance)
- Osmolality and pH ranges
- Clarity/particulate standards
- Endotoxin limits and sterility test results
How does Mannitol 10% dosing form availability compare with alternatives (Mannitol 15% or 20%)?
Supplier switching in shortages may involve moving between strengths, but this can raise:
- compatibility issues with infusion solutions
- protocol deviations in neurocritical care or osmotic therapy
- formulary constraints and nursing administration differences
Procurement teams often stock multiple strengths, but brand and NDC specificity vary by institution and region.
Key Takeaways
- Mannitol 10% is sourced through sterile injectables manufacturers and distributor networks; the effective supplier list is jurisdiction and NDC/container specific.
- Procurement should qualify by strength (10% w/v), dosage form (IV solution), and container type (vial vs bag), then map suppliers to the local MAH and distributor.
- IP risk for “mannitol 10%” is typically lower than for proprietary small molecules, but process, container, and packaging differences can still affect switching.
- Supply disruption risk is driven more by sterile manufacturing capacity and batch release than by exclusivity calendars.
FAQs
- What NDCs should procurement use for Mannitol 10% in the US?
- Are Mannitol 10% infusion bags interchangeable with vial presentations for compatibility and administration?
- How do I verify that a Mannitol 10% supplier meets sterile and endotoxin testing requirements at lot level?
- Do Mannitol 10% shortages occur due to raw material supply, aseptic capacity, or regulatory batch release bottlenecks?
- Which quality documents (COA, sterility, endotoxin, container closure integrity) are required when switching Mannitol 10% suppliers?
References
No sources were provided in the prompt, and no supplier list or regulatory database identifiers (NDCs, MAHs, jurisdictions, container sizes) were included to support citations.
